| 1.63 0.06 (3.82%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.19 |
1-year : | 2.47 |
| Resists | First : | 1.88 |
Second : | 2.11 |
| Pivot price | 1.71 |
|||
| Supports | First : | 1.5 | Second : | 1.24 |
| MAs | MA(5) : | 1.59 |
MA(20) : | 1.71 |
| MA(100) : | 2.44 |
MA(250) : | 2.78 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 8.8 |
| RSI | RSI(14): 40.4 |
|||
| 52-week | High : | 12.68 | Low : | 0.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IXHL ] has closed above bottom band by 32.1%. Bollinger Bands are 38.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.64 - 1.65 | 1.65 - 1.66 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.62 - 1.63 | 1.63 - 1.64 |
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Tue, 10 Sep 2024
Incannex secures financing deal valued at US$60 million - Mugglehead
Tue, 10 Sep 2024
Incannex secures $60 million in funding for clinical trials - Investing.com
Mon, 05 Aug 2024
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Tue, 16 Apr 2024
Incannex Healthcare Inc. Quarterly Update, Q1 2024 - Yahoo Finance
Mon, 05 Feb 2024
Is Incannex Healthcare (NASDAQ:IXHL) In A Good Position To Invest In Growth? - Simply Wall St
Thu, 01 Feb 2024
Incannex Healthcare Inc Share Price - IXHL, RNS News, Articles, Quotes, & Charts (NASDAQ:IXHL) - Proactive Investors UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | -13 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.764e+007 (%) |
| Held by Institutions | 1.203e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.27 |
| Profit Margin | 2 % |
| Operating Margin | 966 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | 155.7 % |
| Qtrly Rev. Growth | 50.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | -1.421e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.29 |
| Price to Sales | 25.61 |
| Price to Cash Flow | 0 |
| Dividend | 65780 |
| Forward Dividend | 13970 |
| Dividend Yield | 4035580% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|